Celecoxib derivative OSU-03012 inhibits the proliferation and activation of hepatic stellate cells by inducing cell senescence

Zhang,Jun; Wang,Miao; Zhang,Zuowei; Luo,Zhongguang; Liu,Fei; Liu,Jie

doi:10.3892/mmr.2014.3048

Celecoxib derivative OSU-03012 inhibits the proliferation and activation of hepatic stellate cells by inducing cell senescence

Authors:
- Jun Zhang
- Miao Wang
- Zuowei Zhang
- Zhongguang Luo
- Fei Liu
- Jie Liu
View Affiliations

Affiliations: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Gastroenterology, Shanghai East Hospital, Shanghai Tongji University School of Medicine, Shanghai 200120, P.R. China
Published online on: December 4, 2014 https://doi.org/10.3892/mmr.2014.3048
Pages: 3021-3026

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver fibrosis may lead to portal hypertension, liver failure or hepatocellular carcinoma, and predominantly results from the proliferation and activation of hepatic stellate cells. OSU‑03012, a non‑cyclooxygenase‑inhibiting celecoxib derivative, has been previously demonstrated to promote apoptosis in certain cell types, however, its function in hepatic fibrosis remains unclear. In the current study, the inhibitory effect of OSU‑03012 on the proliferation of the LX2 human hepatic stellate cell line was evaluated by cell counting kit‑8 assay. Reverse transcription‑quantitative polymerase chain reaction was performed in order to examine the expression of α‑smooth muscle actin and type I collagen, which are representative of LX2 cell activation. The senescence of LX2 cells was measured by senescence‑associated β‑galactosidase staining, and the cell cycle and apoptosis levels were assessed by flow cytometry. The impact of senescence‑associated signaling on protein expression was assessed by western blot analysis. OSU‑03012 was observed to inhibit cell proliferation and prevent the secretion of profibrotic factors in LX2 cells in a dose‑dependent manner. Furthermore, the results demonstrated that OSU‑03012 inhibited the proliferation and activation of LX2 via the induction of cell senescence at the G1 phase, rather than via cell apoptosis. The induction of senescence may be via the upregulation of p16, p21 and p27. In conclusion, the current study provided insight into the pharmacological mechanisms of OSU‑03012 in preventing the proliferation and activation of hepatic stellate cells through cell senescence. The current study supports the theory that OSU‑03012 is a novel agent for potential use against liver fibrosis.

View Figures

View References

1	Bataller R and Brenner DA: Liver fibrosis. J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
2	Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI
3	Campisi J and d’Adda di Fagagna F: Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 8:729–740. 2007. View Article : Google Scholar : PubMed/NCBI
4	Krizhanovsky V, Yon M, Dickins RA, et al: Senescence of activated stellate cells limits liver fibrosis. Cell. 134:657–667. 2008. View Article : Google Scholar : PubMed/NCBI
5	Gao M, Yeh PY, Lu YS, et al: OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res. 68:9348–9357. 2008. View Article : Google Scholar : PubMed/NCBI
6	Johnson AJ, Smith LL, Zhu J, et al: A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood. 105:2504–2509. 2005. View Article : Google Scholar
7	Yacoub A, Park MA, Hanna D, et al: OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol. 70:589–603. 2006. View Article : Google Scholar : PubMed/NCBI
8	McCubrey JA, Lahair MM and Franklin RA: OSU-03012 in the treatment of glioblastoma. Mol Pharmacol. 70:437–439. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kucab JE, Lee C, Chen CS, et al: Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7:R796–R807. 2005. View Article : Google Scholar : PubMed/NCBI
10	Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS and Muscarella P: A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg. 10:207–214. 2006. View Article : Google Scholar : PubMed/NCBI
11	Zhang S, Suvannasankha A, Crean CD, et al: OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res. 13:4750–4758. 2007. View Article : Google Scholar : PubMed/NCBI
12	Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell. 130:223–233. 2007. View Article : Google Scholar : PubMed/NCBI
13	Collado M, Medema RH, Garcia-Cao I, et al: Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem. 275:21960–21968. 2000. View Article : Google Scholar : PubMed/NCBI
14	Wang YC, Kulp SK, Wang D, et al: Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res. 68:2820–2830. 2008. View Article : Google Scholar : PubMed/NCBI
15	Passino MA, Adams RA, Sikorski SL and Akassoglou K: Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science. 315:1853–1856. 2007. View Article : Google Scholar : PubMed/NCBI
16	Adams PD: Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell. 36:2–14. 2009. View Article : Google Scholar : PubMed/NCBI
17	Weng SC, Kashida Y, Kulp SK, et al: Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther. 7:800–808. 2008. View Article : Google Scholar : PubMed/NCBI
18	Zhu J, Huang JW, Tseng PH, et al: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 64:4309–4318. 2004. View Article : Google Scholar : PubMed/NCBI
19	Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 117:539–548. 2007. View Article : Google Scholar : PubMed/NCBI
20	Mayo LD and Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 98:11598–11603. 2001. View Article : Google Scholar : PubMed/NCBI
21	Medema RH, Kops GJ, Bos JL and Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 404:782–787. 2000. View Article : Google Scholar : PubMed/NCBI